Orthopaedic Reparative Surgery Department, Orthopaedic Institute Gaetano Pini, University of Milan, Italy.
Orthopaedic Reparative Surgery Department, Orthopaedic Institute Gaetano Pini, University of Milan, Italy.
Injury. 2014 Feb;45(2):369-73. doi: 10.1016/j.injury.2013.09.014. Epub 2013 Sep 19.
To determine the efficacy of core decompression (CD) technique combined with recombinant morphogenetic proteins, autologous mesenchymal stem cells (MSCs) and xenograft bone substitute into the necrotic lesion of the femoral head on clinical symptoms and on the progression of osteonecrosis of the femoral head.
A total of 38 patients (40 hips) with early stage osteonecrosis of the femoral head were studied over a 4-year period.
CD technique combined with recombinant morphogenetic proteins, autologous MSCs and xenograft bone substitute was associated with a significant reduction in both pain and joint symptoms and reduced the incidence of fractural stages. At 36 months, 33 patients achieved clinical and radiographic healing.
This long-term follow-up study confirmed that CD technique combined with recombinant morphogenetic proteins, autologous MSCs and xenograft bone substitute may be an effective treatment for patients with early stage osteonecrosis of the femoral head.
评估核心减压（CD）技术联合重组形态发生蛋白、自体间充质干细胞（MSCs）和异种骨替代物注入股骨头坏死病灶在改善临床症状和股骨头坏死进展方面的疗效。
对 38 例（40 髋）早期股骨头坏死患者进行了为期 4 年的研究。
CD 技术联合重组形态发生蛋白、自体 MSCs 和异种骨替代物可显著减轻疼痛和关节症状，降低骨折分期发生率。36 个月时，33 例患者获得临床和影像学愈合。
这项长期随访研究证实，CD 技术联合重组形态发生蛋白、自体 MSCs 和异种骨替代物可能是治疗早期股骨头坏死的有效方法。
